Universal reference book for medicines
Name of the drug: FURADONIN AVEXIMA (FURADONIN AVEXIMA)

Active substance: nitrofurantoin

Type: Antibacterial drug, a derivative of nitrofuran.
Uroantiseptic
Manufacturer: AVEKSIMA (Russia) manufactured by IRBITSK HFZ (Russia)
Composition, form of production and packaging
Tablets
yellow or yellow with a greenish tint of color, flat-cylindrical.

1 tab.

nitrofurantoin (furadonin) 50 mg

Auxiliary substances: potato starch - 46.15 mg, silicon dioxide colloid (aerosil) - 2 mg, stearic acid - 1 mg, polysorbate 80 (Tween 80) - 0.85 mg.

10 pieces.
- Packings without cell contour.
10 pieces.
- packings of cellular contour (1) - packs cardboard.
10 pieces.
- packings cellular planimetric (2) - packs cardboard.
10 pieces.
- packings cellular planimetric (3) - packs cardboard.
10 pieces.
- packings cellular planimetric (4) - packs cardboard.
10 pieces.
- packings cellular planimetric (5) - packs cardboard.
20 pcs.
- packings of cellular contour (1) - packs cardboard.
20 pcs.
- banks of dark glass (1) - packs of cardboard.
INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2015.

PHARMACHOLOGIC EFFECT

Antimicrobial agent, a derivative of the group of nitrofurans, primarily for the treatment of urinary tract infections.
It breaks the synthesis of proteins in bacteria and the permeability of the cell membrane. It is active against Gram-positive and Gram-negative bacteria (Staphylococcus spp., Streptococcus spp., Shigella dysenteria spp., Shigella flexneri spp., Shigella boydii spp., Shigella sonnei spp., Escherichia coli, Proteus spp.).
PHARMACOKINETICS

Absorption from the digestive tract is good.
Bioavailability - 50% (food increases bioavailability). The rate of absorption depends on the size of the crystals (microcrystalline form is characterized by rapid solubility and absorption rate, short time of reaching C max in urine). Connection with plasma proteins - 60% .
Metabolised in the liver and muscle tissue.
T 1/2 - 20-25 min. Penetrates through the placenta, GEB, excreted in breast milk. It is excreted completely by the kidneys (30-50% - unchanged).
INDICATIONS

- bacterial infections of the urinary tract (pyelitis, pyelonephritis, urethritis, cystitis);

- prevention of infections in urological operations or examination (cystoscopy, catheterization, etc.).

DOSING MODE

Inside, washing with a lot of water, adults - 0.1-0.15 g, 3-4 times / day;
children - at the rate of 5-8 mg / kg / day, the daily dose is divided into 4 divided doses. Higher doses for adults: single dose - 0.3 g, daily - 0.6 g.
In acute infections of the urinary tract, the duration of treatment is 7-10 days.

Preventive, anti-relapse treatment continues, depending on the nature of the disease, from 3 to 12 months.
The daily dose in this case is 1-2 mg / kg.
SIDE EFFECT

Nausea, vomiting, allergic reactions (lupus-like syndrome, arthralgia, myalgia, anaphylaxis, chills, eosinophilia, rash), dizziness, headache, asthenia, nystagmus, drowsiness, interstitial changes in the lungs, bronchial obstructive syndrome, fever, cough, chest pain , hepatitis, cholestatic syndrome, peripheral neuropathy, pancreatitis, pseudomembranous enterocolitis, rarely - abdominal pain, diarrhea.

CONTRAINDICATIONS

hypersensitivity;

- chronic renal failure;

- Heart failure II-III st .;

- cirrhosis of the liver;

- chronic hepatitis;

- deficiency of glucose-6-phosphate dehydrogenase;

- acute porphyria;

- Pregnancy;

- lactation period;

- Children under 3 years old.

PREGNANCY AND LACTATION

The use of the drug during pregnancy and during breastfeeding is contraindicated.

APPLICATION FOR FUNCTIONS OF THE LIVER

The use of the drug in patients with chronic renal failure is contraindicated.

APPLICATION FOR VIOLATIONS OF THE FUNCTION OF KIDNEYS

The use of the drug for patients with cirrhosis and chronic hepatitis is contraindicated.

APPLICATION FOR CHILDREN

It is forbidden to use the drug for children under the age of 3 years.

Children over 3 years of age are prescribed at the rate of 5-8 mg / kg / day, the daily dose is divided into 4 divided doses.

SPECIAL INSTRUCTIONS

Effect of the drug on the performance of potentially hazardous activities requiring special attention and rapid reactions

During the treatment period, care must be taken when driving vehicles and practicing other potentially hazardous activities requiring increased concentration of attention and speed of psychomotor reactions (with dizziness and drowsiness).

OVERDOSE

Symptoms : vomiting.

Treatment: taking large amounts of fluid leads to an increase in the excretion of the drug with urine.
Effective dialysis.
DRUG INTERACTION

The simultaneous use of nalidixic acid and antacids containing magnesium trisilicate reduces the antibacterial effect.
Incompatibility with fluoroquinolones. Drugs that block tubular secretion, reduce the antibacterial effect (by reducing the concentration of nitrofurantoin in the urine) and increase the toxicity (increases concentration in the blood) of the drug.
TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a dry, protected from light and out of reach of children at a temperature of no higher than 25 ° C.
Shelf life - 4 years.
After the expiry date, the drug should not be used.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!